aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTyr Pharma director Timothy Coughlin received a compensatory stock option grant, giving him the right to acquire 50,000 shares of common stock. The option has an exercise price of $0.95 per share and expires on May 11, 2036.
According to the company’s non-employee director compensation policy, the option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Coughlin continues to serve on the board. After this grant, he holds stock options covering 50,000 shares directly.
aTYR Pharma director Eric Benevich received a new stock option grant. On May 11, 2026, he was awarded options to buy 50,000 shares of aTYR Pharma common stock at an exercise price of $0.95 per share. These options were granted under the company’s non-employee director compensation policy.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board of Directors. Following this grant, he holds 50,000 stock options directly.
aTyr Pharma director Jane A. Gross received a grant of stock options covering 50,000 shares of Common Stock. The options have an exercise price of $0.95 per share and were awarded at no upfront cost as a compensation grant.
The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Gross continues to serve on the Board. After this grant, she holds 50,000 stock options directly according to the filing.
aTYR PHARMA INC director Svetlana Lucas received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and expire on May 11, 2036.
The grant was made under the company’s non-employee director compensation policy. The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. This is a compensation-related award rather than an open-market transaction.
aTYR Pharma director Sara Zaknoen received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and were awarded with no purchase price at grant. They vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. After this award, she holds options for 50,000 shares directly.
aTYR Pharma reported that director Paul Schimmel received a grant of stock options as part of the company’s non-employee director compensation policy. The award covers 50,000 options to buy common stock at an exercise price of $0.95 per share, expiring on May 11, 2036.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 annual stockholders’ meeting, conditioned on his continued board service. Following this grant, Schimmel holds 50,000 stock options directly, and the filing does not show additional derivative holdings.
aTyr Pharma reported preliminary cash, cash equivalents, restricted cash and available-for-sale investments of $68.3 million as of March 31, 2026, and outlined a new pivotal plan for its lead drug efzofitimod in pulmonary sarcoidosis.
Following a Type C meeting with the FDA, the company plans a new global Phase 3 trial in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease, using change in forced vital capacity (FVC) at week 48 as the primary endpoint and the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint.
The 54-week study is expected to enroll about 372 patients on stable low-dose steroids and/or immunosuppressants, with efzofitimod 5.0 mg/kg or placebo given intravenously every three weeks for 17 doses. aTyr intends to file an IND for this C-006 study in June 2026, incorporating enhanced safety monitoring and risk mitigation measures.
aTyr Pharma Inc amendment: The Vanguard Group filed an amended Schedule 13G reporting 0 shares beneficially owned and 0% of the common stock as of the amendment. The filing states Vanguard undertook an internal realignment on January 12, 2026 and, in accordance with SEC Release No. 34-39538, certain subsidiaries will report separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, with an execution date of 03/26/2026. The submission lists Vanguard's principal address in Malvern, Pennsylvania.
aTyr Pharma, Inc. is asking stockholders to vote at its 2026 annual meeting on several key items. Stockholders will elect three Class II directors to terms ending at the 2029 annual meeting, ratify Ernst & Young LLP as auditor for the year ending December 31, 2026, and cast an advisory “say‑on‑pay” vote on compensation for named executive officers.
The company seeks approval of an amendment to its 2015 Stock Option and Incentive Plan to add 4,000,000 shares, bringing the maximum shares reserved under the plan to 19,725,101 and extending the incentive stock option grant period through February 20, 2036. Stockholders are also asked to approve an amendment to the Restated Certificate of Incorporation to increase authorized common stock from 170,000,000 to 340,000,000 shares. The record date for voting is March 16, 2026, when 98,051,212 shares of common stock were outstanding and entitled to vote.